Nuclear Translocation cells are engineered to co-two fusion proteins: a) Enzyme Donor (ED) tagged target protein; b) an Enzyme Acceptor (EA) tagged TAZ domain, derived from the CBP/P300 transcription factor, that localizes to the nucleus. Depending on the assay, activation of the signaling pathway can either a) induce translocation of the ED-tagged target protein into the nucleus, which will force complementation of the two enzyme fragments, and result in the formation of a functional enzyme that will hydrolyze substrate and generate a chemiluminescent signal; or b) induce the ED-tagged protein to vacate the nucleus, resulting in a decrease of functional enzyme and a subsequent decrease of chemiluminescent signal. Some nuclear translocation assays will also co-an untagged secondary protein involved in the pathway of interest. These cells have been modified to prevent long term propagation and expansion using a proprietary compound that has no apparent effect on assay performance.
100 dp(1 x 96-well)/200 dp(2 x 96-well)/1000 dp(10 x 96-well)
Short term (2 weeks): Store in vapor phase of liquid N2
1 x 10^6 cells per vial in 100uL mL (kit contains cells, detection reagents and plate(s))